The UK’s pharmaceutical sector is at a “critical point,” a senior industry figure has warned, as a flight of investment threatens to undermine its status as a global leader. Paul Naish of Sanofi stated that despite its scientific strengths, Britain is now an “expensive” and “terrible” place for drug companies to operate.
This declaration is not just rhetoric; it is backed by a wave of corporate pullbacks. The decision by MSD to scrap its £1bn London R&D hub was a major shock, signaling a deep lack of confidence. This was compounded by Eli Lilly pausing a similar lab project and Sanofi’s own 50% reduction in UK clinical trials.
The industry’s grievances are focused on the UK’s uncompetitive commercial terms. They point to NHS spending on medicines that trails far behind international norms, pricing guidelines that are a quarter of a century out of date, and a revenue clawback system that deters investment.
A consensus is forming that without urgent and radical government action, the decline will accelerate. The call is for a cross-departmental strategy, led by the Treasury, to create a sustainable and attractive environment. The future of one of the UK’s most important economic sectors hangs in the balance.